A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 1/2 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EXPLORATORY EFFICACY OF AOC 1020 ADMINISTERED INTRAVENOUSLY TO ADULT PARTICIPANTS WITH FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
- Registry ID
- AOC 1020-CS1
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- AVIDITY BIOSCIENCES
- Start date
- 2026-02-25
- Completion date
- 2026-03-12
- Last update
- 2023-03-17
Conditions
- FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
Related clinical trials
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE
EFFICACY AND SAFETY OF INTRAVENOUS AOC 1020 FOR THE TREATMENT OF
FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
- A PHASE 2 OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, EFFICACY, AND PHARMACOKINETICS OF AOC 1020 ADMINISTERED
INTRAVENOUSLY TO ADULT PARTICIPANTS WITH FACIOSCAPULOHUMERAL MUSCULAR
DYSTROPHY (FSHD)
- A BICENTRIC, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PILOT STUDY TO EVALUATE
THE EFFICACY AND SAFETY OF SATRALIZUMAB IN FSHD1
- A PHASE 1/2A DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ARO-DUX4 IN ADULT PATIENTS AND ADOLESCENT PATIENTS WITH FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY TYPE 1
- A PHASE 1/2A DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ARO-DUX4 IN ADULT PATIENTS WITH FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY TYPE 1
- AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFECTS OF ACE-083 IN PATIENTS WITH FSHD PREVIOUSLY ENROLLED IN STUDY A083-02 AND IN PATIENTS WITH CMT DISEASE TYPES 1 AND X PREVIOUSLY ENROLLED IN STUDY A083-03
View on source registry